BioCardia, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BCDA Nasdaq 2836 www.biocardia.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioCardia, Inc.

BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart - Feb 10th, 2026 7:15 am
BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT) - Feb 3rd, 2026 6:00 am
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA - Dec 16th, 2025 6:00 am
BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno - Dec 3rd, 2025 6:00 am
BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress - Dec 1st, 2025 6:30 am
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality - Nov 24th, 2025 6:15 am
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results - Nov 12th, 2025 2:40 pm
BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial - Nov 10th, 2025 6:30 am
BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025 - Nov 5th, 2025 5:29 pm
BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial - Oct 30th, 2025 6:00 am
BioCardia Inc. (BCDA): 2025 Product Pipeline and Strategy Analysis Report - Oct 21st, 2025 10:05 am
BioCardia Regains Compliance with Nasdaq Listing Requirements - Oct 2nd, 2025 6:00 am
BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure - Sep 22nd, 2025 6:00 am
Bullish BioCardia Insider Buying Worth US$1.06m Yet To Pay Off - Sep 20th, 2025 8:54 am
BioCardia Announces Pricing of Up To $12 Million Public Offering - Sep 18th, 2025 7:15 am
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up - Sep 18th, 2025 5:00 am
BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025 - Sep 4th, 2025 7:00 am
BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D™ Fusion Imaging for Interventional Cardiology - Aug 13th, 2025 6:00 am
BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results - Aug 11th, 2025 7:15 am
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 - Aug 6th, 2025 1:18 pm